Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Current Leases (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Current Leases data on record, last reported at $2.5 million in Q1 2026.

  • On a quarterly basis, Current Leases rose 9.92% to $2.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.5 million, a 9.92% increase, with the full-year FY2025 number at $2.4 million, up 9.97% from a year prior.
  • Current Leases reached $2.5 million in Q1 2026 per FULC's latest filing, up from $2.4 million in the prior quarter.
  • Over the last five years, Current Leases for FULC hit a ceiling of $2.7 million in Q1 2023 and a floor of $2.0 million in Q1 2024.
  • A 5-year average of $2.3 million and a median of $2.3 million in 2023 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: soared 60550.0% in 2022, then fell 23.7% in 2024.
  • Tracing FULC's Current Leases over 5 years: stood at $2.6 million in 2022, then dropped by 15.76% to $2.2 million in 2023, then decreased by 0.27% to $2.2 million in 2024, then increased by 9.97% to $2.4 million in 2025, then increased by 2.37% to $2.5 million in 2026.
  • Business Quant data shows Current Leases for FULC at $2.5 million in Q1 2026, $2.4 million in Q4 2025, and $2.3 million in Q3 2025.